Goldenwell Biotech, Inc. (GWLL)

Market Cap	51.48M
Revenue (ttm)	62.34K +117,526.4%
Net Income	-75.12K
EPS	-0.00
Shares Out	99.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,250
Open	0.5200
Previous Close	0.5200
Day's Range	0.5200 - 0.5200
52-Week Range	0.3880 - 10.0000
Beta	4.29
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 12, 2026

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2019
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: GWLL

Financial Performance

In 2024, Goldenwell Biotech's revenue was $139, a decrease of -92.43% compared to the previous year's $1,836. Losses were -$131,498, 12.0% more than in 2023.